Olema Pharmaceuticals, Inc.
OLMA
$27.44
$0.291.05%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.93M | 3.96M | 4.25M | 4.47M | 4.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.88M | 37.86M | 34.87M | 36.77M | 37.62M |
| Operating Income | -45.88M | -37.86M | -34.87M | -36.77M | -37.62M |
| Income Before Tax | -42.22M | -43.78M | -30.39M | -33.57M | -34.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.22M | -43.78M | -30.39M | -33.57M | -34.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.22M | -43.78M | -30.39M | -33.57M | -34.56M |
| EBIT | -45.88M | -37.86M | -34.87M | -36.77M | -37.62M |
| EBITDA | -45.83M | -37.73M | -34.75M | -36.65M | -37.53M |
| EPS Basic | -0.49 | -0.51 | -0.36 | -0.51 | -0.60 |
| Normalized Basic EPS | -0.31 | -0.25 | -0.22 | -0.32 | -0.38 |
| EPS Diluted | -0.49 | -0.51 | -0.36 | -0.51 | -0.60 |
| Normalized Diluted EPS | -0.31 | -0.25 | -0.22 | -0.32 | -0.38 |
| Average Basic Shares Outstanding | 85.73M | 85.50M | 85.43M | 65.79M | 57.26M |
| Average Diluted Shares Outstanding | 85.73M | 85.50M | 85.43M | 65.79M | 57.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |